Since the discovery of the antiherpetic activity of acyclovir (ACV) (8, 25) , the drug has been used extensively for a variety of human herpetic infections (7) . Resistance to ACV has been reported to occur both in vitro (3, 5, 28) and in vivo (2, 4, 26, 31) . In both settings, the most frequently encountered ACV-resistant herpes simplex virus (HSV) mutant is defective in its ability to induce thymidine kinase (TK). However, the substantial reduction in virulence that accompanies the loss of this important virus-coded enzyme renders these viruses less clinically significant (11, 12, 31) . Other types of ACV-resistant mutants that retain TK activity were only a theoretical possibility until in vitro systems were devised for their selection and isolation (6) . One such mutant contains alterations in the viral DNA polymerase that make it insensitive to ACV triphosphate (13, 17) . A second type results from mutations in the TK gene that cause the induction of a TK enzyme with altered substrate specificity (6, 15, 16) . ACV-resistant viruses representing both of these classes were initially isolated in vitro, and their retention of virulence was confirmed in animal systems (6, 17) . More recently, similar mutants have been recovered from two patients receiving ACV therapy (10, 22) . However, despite their pathogenicity, their clinical significance remains un- clear.
Primary infection with HSV or reactivation of latent HSV can be life-threatening in patients whose immune systems are compromised: organ transplant recipients, patients receiving cancer chemotherapy, and patients infected with human immunodeficiency virus. The heterogeneity of HSV type 1 (HSV-1) clinical isolates (23) increases the possibility that established lesions in the immunocompromised host may contain both ACV-susceptible and ACV-resistant virus. Because such patients cannot depend on immune elimination of the initially few resistant viruses, ACV treatment could readily select less susceptible virus present in the lesions (1).
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Several reports in the literature describe isolation of ACVresistant virus from this patient group (2, 4, 26, 32) .
In view of the potential clinical significance of pathogenic mixtures of ACV-susceptible and ACV-resistant viruses, we have evaluated their behavior in athymic mice. This model has proven to be clinically relevant in examining the pathogenicity of resistant isolates (26) . This paper describes infection of athymic mice with defined mixtures of TKpositive (TK+) and TK-deficient (TKD) or 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (GIBCO Laboratories, Grand Island, N.Y.), sodium bicarbonate, 75 U of pencillin G, and 75 ,ug of streptomycin per ml.
Viruses. The virus strains used were 3-times-plaque-purified HSV-1 clinical isolates, designated here by virus laboratory (VL) numbers 9013 and 9014. The origin of these isolates has been reported previously (26) . These viruses were obtained from an immunodeficient child and represent pre-and posttherapy virus isolates. VL 9014 is TK+ and ACV susceptible, while VL 9013 is TKD and ACV resistant. A third HSV-1 strain (VL 8971) was used in these studies; originally designated SC16-S1, it is a TKA laboratory strain that has been described previously (6) . (26) and the dye uptake (DU) method (19) (19) . However, in the PR assay, ACV-resistant viruses had ED50s of .1.0 ,ug/ml. Additionally, the nature of sition. An increase to 9% TKD resulted in a 7.4-fold increase (0.5 to 3.7 ,ig/ml) in ACV ED50 by the DU assay, an additional 21% TKD virus resulted in another 16.2-fold increase (0.5 to 8.1 jig/ml) in the ACV ED50 When the same mixtures were tested for ACV susceptibility by the PR method, there was a 1.4-fold increase (0.5 to 0.7 jig/ml) and 2-fold increase (0.5 to 1.0 ,ug/ml), respectively, in the ACV ED50s. This difference may reflect the greater amount of input virus used in the DU assay (=--500 PFU) than in the PR assay (100 to 200 PFU/ml) or may be the result of the different endpoints used in the assay.
Pathogenicity of plaque-purified viruses for athymic mice.
Mice were infected on the snout with approximately 105 PFU of the appropriate virus strain. Herpetic lesion scores and virus titers in snout tissue are shown in Table 2 . TK+ and TKA viruses showed similar abilities to produce progressive cutaneous disease in athymic mice. Lesions were most severe 6 to 8 days after virus inoculation, with an approximate 4-log increase in virus titers in snout skin between days 0 and 4. On the other hand, TKD virus had greatly reduced ability to cause cutaneous disease, with peak lesion scores of 1.2 on day 5 and a 0.6-log increase in virus skin titer between days 0 and 4. These results confirm earlier reports (11, 12) (Table 5 ). For example, untreated mice infected with the TK+-TKD mixture exhibited two types of disease. The first, a rapidly progressive fatal disease, as observed in mouse M4, was associated with 100% TK+ and ACV-susceptible virus (ACV ED50, 0.8 ,ug/ml by DU). The second was indolent disease associated with 100% TKD, ACV-resistant (ACV ED50, 12.0 ,ug/ml by DU) virus, as noted in mouse M8. Prophylactic treatment of mice infected with this mixture selected for TKD virus (ACV ED50, 16 .0 ,ug/ml), as exemplified by mouse M2 on day 10. Removal of this selective influence, however, allowed the reemergence of the more "natural" virus, and by day 17, 8 days after therapy was stopped, virus isolated from the same mouse was 97% TK+ and 3% TKD, with an ACV ED50 of 0.9 ,ug/ml. Delayed ACV treatment of mice infected with the TK+-TKD mixture produced variable clinical responses dependent on lesion severity at the time of treatment. For example, mouse M3 had a lesion score of 1.0 on day 4, when treatment was started. On day 6, virus recovered from this mouse was 100% TK+ and ACV susceptible (ACV ED50, 0.4 ,ug/ml), and the lesion had progressed to a score of 3.0. When the same mouse was tested on days 10 and 17, the virus recovered continued to be predominantly TK+ and ACV Table 6 . In contrast, mouse M6, treated prophylactically with ACV at 0.25 mg/ml, had severe disease 6 days after infection, with a lesion score of 3.0. Virus recovered from this animal was ACV resistant (ACV ED50, 34.4 ,ug/ml by DU) and consisted of 5% TK+, 5% TKD, and 90% TKA. This animal died shortly after this mixture of viruses was isolated. Another animal (mouse M9) had a more satisfactory response to ACV, with ACV-resistant virus (ACV ED50, 9.1 p.g/ml by DU) isolated on day 10. By day 16, the ACV ED50 of virus recovered from this animal had decreased to 4.8 ,ug/ml, and this change was associated with a shift from 60% TK+-40%'TKD on day 10 to 97% TK+-3% TKD on day 16. Mice receiving a higher dose of prophylactic ACV (1.25 mg/ml) had more complete responses to treatment. Viruses obtained from these mice were 100% TKD with one exception: on day 17, the isolate from mouse M9 contained 10% VOL. 33, 1989 on June 21, 2017 by guest http://aac.asm.org/ Downloaded from TK+ and 90% TKD virus, although it was still highly resistant (ACV ED50, 26.4 ,ug/ml).
In animals treated prophylactically with the lowest dose of ACV, TKA virus could emerge and cause clinical disease (as in mouse M6). At higher ACV doses, no animals had lesions attributable to TKA virus.
Low-dose, delayed ACV treatment produced responses in mice infected with the TK+-TKD-TKA mixture similar to those observed in the previous experiments with the less complexly defined population. Animals with severe lesions at the time of treatment responded poorly and succumbed to overwhelming TK+ infection (e.g., mouse M9). Mice with less severe disease (lesion score on day 4, <1.0) had their disease stabilized during treatment. Virus recovered from these animals was predominantly TK+ and ACV susceptible, e.g., VL 11220 isolated from mouse M3.
Higher doses of delayed ACV therapy (1.25 mg/ml) caused striking differences in the viruses recovered from individual mice. For example, mouse Ml had a lesion score of 2.0 when therapy was started on day 4. His lesions continued to progress while on therapy, and on day 10 his lesion score was 3.0. The virus recovered on day 10 was ACV resistant (ACV ED50, 12.2 ,ug/ml by DU) and was 1% TK+ and 99% TKA by [1251I]dC plaque autoradiography. A second mouse, M3, had insignificant disease when treatment was started. Lesions progressed to a score of 1.0 on day 5, when they began to stabilize. Virus recovered from lesions on day 6 was ACV resistant (ACV ED50, 9.2 ,ug/ml by DU) and 1% TK+ and 98% TKD. When therapy was stopped (day 14), lesions again progressed. On day 16, virus isolated from the lesions of mouse M3 was still ACV resistant (ACV ED50, 10.1 ,ug/ml by DU), but the amount of TK+ virus had increased from 1 to 69%.
In summary, disease patterns and clinical outcome varied somewhat even within mice of the same group. Although mice in the two separate experiments were infected in similar manners with the defined mixtures, individual patterns of disease were largely dependent on the TK phenotype of the virus that predominated in individual mice. TK+ virus and TK virus were associated with progressive disease or "breakthrough" lesions in low-dose-treated mice and in animals receiving delayed treatment for severe lesions. In contrast, TKD virus caused indolent, chronic lesions in untreated mice and in prophylactically treated animals. Lesions were quickly recolonized by TK+ virus after treatment was stopped.
DISCUSSION
The recent reports of pathogenic, ACV-resistant mutants isolated from normal and immunocompromised patients (10, 22) have caused renewed concern about clinical resistance to ACV. This issue has resurfaced because of the current acquired immunodeficiency syndrome epidemic and the subset of these patients who are receiving ACV for HSV infections (21) .
Numerous reports have appeared recently that evaluate methods for the detection of ACV-resistant virus. These methods include an enzyme assay which determines the uptake of labeled drug in HSV-infected cells (28) , plaque autoradiography with labeled substrates (8, 30) , and various drug susceptibility assays with different endpoints of viral growth. Our data indicate that assays that require higher concentrations of virus as well as increased culture time (>48 h) may be more sensitive for detecting small amounts of resistant virus.
Harmenburg et al. (14) reported that the enzymatic method can detect approximately 6.2% TKD virus after 24 h of incubation; with increasing incubation times, it can detect even smaller amounts of TKD virus. Our results with the DU assay indicate that it can usually detect between 3 and 9% of ACV-resistant virus and, when coupled with [125I]dC plaque autoradiography, is a very precise method for the detection and identification of ACV-resistant mutants. For our purposes, the absolute numerical value of the ED50 is less important than the detection and definition of small numbers of less-sensitive viruses.
Cutaneous HSV infection of athymic mice is a reasonable model of severe virus infection in the immunocompromised host. Defects in T-cell-mediated immunity of humans appear to increase the risk of HSV infection (20, 24, 33) , and in athymic mice, HSV infection is almost uniformly fatal, while mice with intact immune responses appear to recover completely. In addition, these mice are quite susceptible to infection with a range of ACV-resistant mutants, whereas ACV-resistant TKD viruses replicate poorly in normal mice (26) .
Infections the dose used (0.5 mg/ml). These findings confirm the potential for clinically significant illness as a result of infection with pathogenic ACV-resistant TKA HSV strains in immunocompromised patients.
Our results with viruses recovered from individual mice infected with defined mixtures emphasize the difficulty associated with the characterization of heterogeneous clinical isolates. It was not always possible to predict the types of viruses that would be recovered from individual mice infected with the same mixture. As noted in a previous report (11) , virus mixtures recovered from infected mice tended to be more heterogeneous and generally more resistant than virus mixtures prepared in vitro. Clearly, the selective conditions differ in vivo and in vitro. For instance, it has been reported (9) that nucleosides are metabolized quite differently in cells from different species, which can lead to quite different levels of the active molecules. Also, it is possible that more subtle changes in the viruses, somehow associated with changes in other genes, may create additional disadvantages in vivo. However, observation of the disease pattern in infected mice enables a reasonable prediction of the TK phenotype that predominates in individual mice.
TKD viruses were found in chronic, indolent ulcers of surviving, untreated mice that had been infected with predominantly TK+ virus. These TKD mutants were also found in prophylactically treated mice late in the course of therapy. Our observations are similar to reports of TKD virus patterns of infection in marrow transplant patients (2, 4) . Interestingly, when therapy was stopped, TK+ virus rapidly rees-tablished itself in the lesion. This suggests that in some non-life-threatening clinical situations, it might be possible to stop treatment, allow regrowth of TK+ virus, and then restart therapy.
In agreement with earlier reports, delayed therapy (96 h or longer) for severe herpetic disease was of little clinical benefit (9) , and established lesions harboring wild-type virus were slow to respond to low doses of oral ACV. However, a fivefold increase in ACV dose enhanced the response to delayed therapy.
Pathogenic TKA virus was responsible for progressive disease in mice receiving low-dose (0.25-mg/ml) prophylactic ACV or high-dose (1.25-mg/ml) delayed ACV treatment. Although this mutant was recovered from only a few mice, it caused severe disease and death in the animals from which it was isolated. At present, there are no clinical reports of progressive herpetic disease in patients harboring similar mutants, and some studies indicate that these viruses may respond to other nucleoside analogs (10) .
There are a number of significant differences between cutaneous disease in athymic mice and HSV disease in immunocompromised patients. For example, in athymic mice virus is introduced as a primary infection that, because of a lack of T-cell-dependent immunity, progresses to the central nervous system and kills the animals. In immunocompromised humans, HSV is usually a recurrent infection, with little central nervous system involvement. Recovery from infection generally depends on reestablishment of normal T cell function (24) . Additionally, most immunocompromised patients receive parenteral ACV, which yields levels in plasma considerably higher than can be achieved in athymic mice receiving oral ACV therapy (26) . Despite these differences, the athymic mouse is a useful model for studying the interactions of different components of a viral population, and this model may predict the selection, pattern of infection, and clinical outcome of HSV infections in immunocompromised patients.
